Effects of Biologic Therapies for Cutaneous Inflammatory Diseases in HIV-Infected Individuals: Reliable or Not?

AKARSU S., Avci C.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, vol.2, no.3, pp.61-67, 2018 (ESCI) identifier

  • Publication Type: Article / Review
  • Volume: 2 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.30621/jbachs.2018.357
  • Journal Name: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.61-67
  • Keywords: human immunodeficiency virus, cutaneous inflammatory diseases, psoriasis and psoriatic arthritis, hidradenitis suppurativa, pemphigus vulgaris, biologic therapy, HUMAN-IMMUNODEFICIENCY-VIRUS, ACTIVE ANTIRETROVIRAL THERAPY, PSORIATIC-ARTHRITIS, ETANERCEPT, PATIENT, USTEKINUMAB, ADALIMUMAB, RITUXIMAB, SAFETY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Purpose: Patients with cutaneous inflammatory diseases often present with more aggressive and refractory clinical course in the presence of accompanying human immunodeficiency virus (HIV) infection. Therefore, biologic therapies may be needed to improve outcomes of these patients. The use of biologic agents in HIV positive patients is conflicting because such treatment can lead to increase the risk of infection and malignancy in already immunocompromised patients. On the other hand, some researchers have recommended that HIV management should also include the blockade of tumour necrosis factor-alpha (TNF-alpha). We discuss the reliability and effectiveness of biologic therapies for patients with cutaneous inflammatory diseases and accompanying HIV infection.